No evidence for an effect of the CCR5 Δ32/+ and CCR2b 64I/+ mutations on human immunodeficiency virus (HIV)-1 disease progression among HIV-1- infected injecting drug users

Journal of Infectious Diseases

Volumn 179, Issue 4, 1999, Pages 825-831

  Schinkel, Janke ^a   Langendam, Miranda W ^c   Coutinho, Roel A ^c   Krol, Anneke ^c   Brouwer, Margreet ^c   Schuitemaker, Hanneke ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DRUG ABUSE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; SEROPREVALENCE; VIRUS INHIBITION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; GENOTYPE; HIV-1; HUMANS; MALE; MUTATION; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RECEPTORS, CYTOKINE; SUBSTANCE ABUSE, INTRAVENOUS; VIREMIA;

EID: 0032932463     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314658     Document Type: Article

References (39)

1. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein coupled receptor. Science 1996; 272:872-7.
2. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M. Molecular cloning and functional expression of a new human CC-chemokine receptor gene. Biochemistry 1996; 35:3362-7.
3. Deng HK, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-6.
4. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667-73.
5. Doranz BJ, Rucker J, Yi Y, et al. A dual tropic primary HIV-1 isolate that uses fusin and the beta-chemokines receptors CKR-5, CKR-3, and CKR - 2b as fusion factors. Cell 1996; 85:1149-58.
6. Benkirane M, Jin DY, Chun RF, Koup RA, Jeang KT. Mechanism of trans dominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem 1997; 272:30603-6.
7. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-62.
8. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiple-exposed individuals to HIV-1 infection. Cell 1996; 86:367-77.
9. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-5.
10. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2:1240-3.
11. Quillent C, Oberlin E, Braun J, et al. HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998; 351:14-8.
12. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997; 277:959-65.
13. Rizzardi GP, Morawetz RA, Vicenzi E, et al. CCR2 polymorphism and HIV disease. Nat Med 1998; 4:252-3.
14. Kostrikis LG, Huang Y, Moore JP, et al. A chemokine receptor CCD2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med 1998; 4:350-3.
15. van Rij RP, de Roda Husman AM, Brouwer M, Goudsmit J, Coutinho RA, Schuitemaker H. Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants. J Infect Dis 1998; 178:1806-11.
16. Spijkerman IJB, Koot M, Prins M, et al. Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users compared with homosexual men. AIDS 1995; 9:1085-92.
17. van Haastrecht HJA, van Ameijden EJC, van den Hoek JAR, Mientjes GHC, Bax JS, Coutinho RA. Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users. Am J Epidemiol 1996; 143:380-91.
18. de Roda Husman AM, Koot M, Cornelissen M, et al. Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med 1997; 127:882-90.
19. Koot M, Vos AH, Keet IPM, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992; 6:49-54.y
20. Van Gemen B, van Beuningen R, Nabbe A, et al. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J Virol Methods 1994; 40:157-67.
21. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987; 36(Suppl 1):1S-15S.
22. Prins M, Hernandez Aguado I, Brettle RP, et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS 1997; 11:1747-56.
23. Jongbloed G. The iterative convex minorant algorithm for nonparametric estimation. Delft, The Netherlands; Delft University of Technology, 1995 (technical report).
24. Groeneboom P, Wellner JA. Information bounds and non parametric maximum likelihood estimation. Berlin: Birkhäuser Verlag, 1992.
25. Michael NL, Chang G, Louie LG, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997; 3:338-40.
26. SAS Institute. SAS/STAT software; changes/enhancements through release 6.11. Cary, NC: SAS Institute, 1996.
27. Galai N, Muñoz A, Chen K, Carey VJ, Chmiel J, Zhou SYJ. Tracking of markers and onset of disease among HIV-1 seroconverters. Stat Med 1993; 12:2133-45.
28. + decline among HIV-infected injecting drug users. Drug Alcohol Depend (in press).
29. Eugen-Olsen J, Iversen AK, Garred P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 1997; 11: 305-10.
30. + T cells. Science 1995; 270:1811-5.
31. Zagury D, Lachgar A, Chams V, et al. C-C chemokines, pivotal in protection against HIV type 1 infection. Proc Natl Acad Sci USA 1998; 95:3857-61.
32. Mientjes GHC, Miedema F, van Ameijden EJC, et al. Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. AIDS 1991; 5:35-41.
33. Amara A, Le Gall S, Schwartz O, et al. HIV coreceptor downregulation as antiviral principle: SDF-1a-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J Exp Med 1997; 186:139-46.
34. Franci C, Gosling J, Tsou CL, Coughlin SR, Charo IF. Phosphorylation by a G protein-coupled kinase inhibits signaling and promotes internalization of the monocyte chemoattractant protein-1 receptor. Critical role of carboxyl-tail serines/threonines in receptor function. J Immunol 1996; 157: 5606-12.
35. Pehrson P, Lindbäck S, Lidman C, Gaines H, Giesecke J. Longer survival after HIV infection for injecting drug users than for homosexual men: implications for immunology. AIDS 1997; 11:1007-12.
36. Multicohort analysis project workshop. Part I. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. AIDS 1994; 8:911-21.
37. Spijkerman IJB, Langendam MW, Veugelers PJ, et al. Differences in progression to AIDS between injection drug users and homosexual men with documented dates of seroconversion. Epidemiology 1996; 7:571-7.
38. Prins M, Veugelers PJ. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV - 1 seroconversion. European seroconverter study and the Tricontinental Seroconverter Study. AIDS 1997; 11:621-31.
39. Lukashov VV, Kuiken CL, Vlahov D, Coutinho RA, Goudsmit J. Evidence for HIV type 1 strains of US intravenous drug users as founders of AIDS epidemic among intravenous drag users in Northern Europe. AIDS Res Hum Retroviruses 1996; 12:1179-83.